7/102 sources · 2 publishersUpdated Oct 26, 11:52 UTC
Xilio begins Phase 1/2 testing of XTX501 in metastatic lung cancer
Xilio Therapeutics reported on October 26, 2026 that it had dosed the first participant in a Phase 1/2 study of XTX501. The bispecific therapy combines PD-1 blockade with masked IL-2 and is being tested in metastatic non-small cell lung cancer after prior anti-PD(L)-1 treatment. Xilio expects initial Phase 1 data in Q4 2027, while the U.S. multicenter trial evaluates safety and tolerability.
Why it matters
The trial start gives investors a defined development milestone and a stated Q4 2027 timeframe for initial data. The materials report no clinical results from the study yet.
Key facts
- 1Xilio has started dosing in a Phase 1/2 clinical study of XTX501 for metastatic non-small cell lung cancer. tradingview.com
- 2The company expects initial Phase 1 data in Q4 2027. tradingview.com
- 3The U.S. study is multicenter and open-label and is assessing XTX501 as a monotherapy in metastatic non-small cell lung cancer and select advanced solid tumors. investing.com
- 4The trial is evaluating safety and tolerability in patients who previously received anti-PD(L)-1 therapy. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.